Chronic Hepatitis C: Current Status and Rationale for Antiviral Therapy

References

• Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo GL. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997; 26(3 suppl 1): 137s–142s.
   Google Scholar
• Alter MJ, Mast BE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437–455.
   PubMed Web of Science ®Google Scholar
• Alter MJ, Mast BE. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1(3): 559–568.
   PubMedGoogle Scholar
• Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264: 2231–2235.
   PubMed Web of Science ®Google Scholar
• Atler MJ. Epidemiology of hepatitis C in the West. Sem Liver Dis 1995; 15: 5–14.
   Google Scholar
• Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-alpha on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A, non-B hepatitis: A meta-analysis. Clinical Drug Investigation 1995; 9(5): 239–254.
   Google Scholar
• Bonis PAL, Ioannidis JPA, Cappelleri JC, Kaplan MM, Lau, J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatol-ogy 1997; 26(4): 1035–1044.
   Google Scholar
• Bukh J, Miller RH, Purcell RH: Genetic heterogeneity of hepatitis C virus: Qauasispecies and genotypes. Semin Liver Dis 1995; 15: 41–63.
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Linea C, Pagliaro L. the effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. Journal of Hepatology 1997; 26(6): 1187–1199.
   Google Scholar
• Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of rando-mized controlled trials. American Journal of Gastro-enterology 1999.94(3): 581–595.
   Google Scholar
• Carithers RL and Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26(3 suppl 1): 83s–88s.
   Google Scholar
• Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effects of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. Journal of Hepatology 1995; 23 (suppl 2): 8–12.
   Google Scholar
• Choo QL, Kuo G, Weiner AJ, et al: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–361.
   PubMed Web of Science ®Google Scholar
• Davis GL. Treatment of acute and chronic hepatitis C. Clinics in Liver Disease 1997; 1(3): 615–630.
   Google Scholar
• Davis GL, Hoofnagle JH: Interferon in viral hepatitis: Role in pathogenesis and treatment. Hepatology 1986; 6(5): 1038–1041.
   Google Scholar
• Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenhei-mer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321(22): 1501–1506.
   Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group. N Eng J Med 1998; 339(21): 1493–1499.
   Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321(22): 1506–1510.
   Google Scholar
• Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. Journal of Hepatology 1996; 24(1): 38–47.
   PubMed Web of Science ®Google Scholar
• Glue P. The clinical pharmacology of Ribavirin. Seminars in Liver Disease 19991; 19(1): 17–24.
   Google Scholar
• Gonzalez-Peralta RP, Qian K, She YS, et al. Clinical implications of viral quasispecies in chronic hepatitis C. J Med Virol 1996: 49; 242–247.
   Google Scholar
• Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, Witt K, Blatt LM. Retreatment of chronic hepatitis C with consensus inter-feron. Hepatology 1998; 27(4): 1136–1143.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Bisceglie AD, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315(25): 1575–1578.
   PubMed Web of Science ®Google Scholar
• Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, et al. Interrelation-ship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675.
   PubMed Web of Science ®Google Scholar
• Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111(5): 1307–1312.
   PubMed Web of Science ®Google Scholar
• Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28(4): 1121–1127.
   PubMed Web of Science ®Google Scholar
• Lee WM, Reddy KR, Tong MJ, Black M, Van Leeuwen DJ, Hollinger FB, Mullen KD, Pimstone N, Alber D, Gardner S. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepa-titis C. The Consensus Interferon Study Group. Hepa-tology 1998; 28(5): 1411–1415.
   Google Scholar
• Lindsay KL. Therapy of Hepatitis C: Overview. Hepatology 1997; 26(3 suppl 1): 71s–77s.
   Google Scholar
• Maddrey WC. Safety of combination interferon alfa-2b/ ribavirin therapy in chronic hepatitis c-relapsed and treatment-naïve patients. Seminars in Liver Disease 1999; 19(1): 67–75.
   Google Scholar
• Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato BA. Interferon-alpha treatment in patients with chronic hepatitis C: a meta-analytic evaluation. Clinical Drug Investigation 1995; 9(3): 141–149.
   Google Scholar
• Marcellin P, Boyer N, Giiostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human alpha-interferon in patients with chronic non-A, non-B, hepatitis: a multi-center randomized controlled trial from France. Hepa-tology 1991; 13(3): 393–397.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine 1997; 127(10): 875–881.
   Google Scholar
• Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine 1997; 127(10): 875–881.
   Google Scholar
• McHutchinson, JG, Gordon MD, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–1492.
   Google Scholar
• McHutchison JG and Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Seminars in Liver Disease 1999; 19(1): 57–65.
   Google Scholar
• McQuillan G, Alter M, Moyer L, Lambert S, Margolis H. A population based serologic study of hepatitis C virus infection in the United States. Proceedings of the IX International Symposium on Viral Hepatitis and Liver Disease, Rome, 1996; p. 8.
   Google Scholar
• Niederau C, Heintges T, and Haussinger D. Treatment of chronic hepatitis C with a-interferon: an analysis of the literature. Hepato-Gastroenterology 1996; 43(12): 1544–1556.
   Google Scholar
• Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. Journal of Hepatology 1996; 25(3): 283–291.
   PubMedGoogle Scholar
• Patterson J, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990; 12: 1132–1146.
   Google Scholar
• Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt, JJ, Selves J, Banange K, et al. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitment du Virus De L'hepatite C (Get.Vhc). Hepatology 1998; 28(6): 1680–1686.
   Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349(9055): 825–832.
   Google Scholar
• Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen IL, Sajus M, Costa TM. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332(22): 1457–1462.
   Google Scholar
• Poynard T, Leroy V, CohardM, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24(4): 778–789.
   Google Scholar
• Poynard, T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352(9138): 1426–1432.
   Google Scholar
• Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058–1061.
   PubMed Web of Science ®Google Scholar
• Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351(9096): 83–87.
   Google Scholar
• Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, De Micheli AG, Donegani E, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. Journal of Hepatology 1990; 11\(suppl 1): s43–s49.
   Google Scholar
• Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. Journal of Hepatology 1997; 26(5): 961–966.
   Google Scholar
• Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. Journal of Hepatology 1997; 26(5): 961–966.
   Google Scholar
• Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 1996; 23: 205–209.
   Google Scholar
• Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. Journal of Hepatology 1991; 13(2): 192–199.
   Google Scholar
• Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466
   PubMed Web of Science ®Google Scholar
• Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341(12): 866–870.
   PubMed Web of Science ®Google Scholar